Aquestive Therapeutics Inc.’s (AQST) APL-130277, proposed as an intermittent therapy to overcome episodic off periods in Parkinson's disease, awaits the FDA decision on January 29, 2019.APL-130277 is a sublingual film formulation of Apomorphine, a non-ergot dopamine agonist.Sunovion Pharmaceuticals Inc. is Aquestive Therapeutics’ partner and sponsor of APL-130277.If approved, APL-130277 is expected to bring in peak sales of $700 million. Oral Levodopa is the “Gold Standard” therapy for Parkinson's disease. Over time, as the disease progresses, the medication fails to work optimally, resulting in the re-emergence of symptoms (motor and non-motor) otherwise controlled by it. These periods are referred to as OFF episodes.OFF episodes are characterized, in part, by tremor, stiffness or slow movement. These episodes may disrupt a person’s ability to perform everyday activities and may be burdensome for patients, family and caregivers.AbbVie Inc.’s Duopa, which is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine; Apokyn, an injectable drug; Deep brain stimulation and Surgical treatment are some of the currently available treatment options for Parkinson disease patients with OFF periods.Acorda Therapeutics Inc.’s (ACOR) Inbrija was approved as recently as December 21, 2018 for the treatment of OFF episodes in people with Parkinson’s disease taking a carbidopa/levodopa regimen.AQST closed Friday’s (Dec.21, 2018) trading at $6.51, down 5.65%.